Iron Sucrose

Summary

Iron Sucrose (CHEMBL1200823) is an approved small molecule (ATC B03AB02); indicated across 5 conditions including iron deficiency anemia and chronic kidney disease.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: B03AB02
• Indications: 5 conditions
• Clinical trials: 56

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200823
Name	Iron Sucrose
Type	Small molecule
Max phase	4
ATC	B03AB02

Also known as: Ferric hydroxide sucrose complex, Iron oxide saccharated, Iron saccharate, Iron sucrose, Iron sucrose complex, Iron sugar, Iron(iii) hydroxide sucrose complex, Saccharated ferric oxide, Saccharated iron, Saccharated iron oxide, XI-921, IRON SUCROSE

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

5 indications (3 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
iron deficiency anemia	4	MONDO:0001356	HP:0001891
chronic kidney disease	4	MONDO:0005300	EFO:0003884
anemia	4	MONDO:0002280	EFO:0004272
pulmonary arterial hypertension	2	MONDO:0015924	EFO:0001361
lymphoid neoplasm	2	MONDO:0005157	EFO:0001642

Clinical trials

Total trials: 56.

Phase distribution

Phase	Trials
PHASE4	15
Not specified	15
PHASE3	14
PHASE2	9
PHASE1	2
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00204256	PHASE4	UNKNOWN	Intravenous Iron in Patients With Anemia of Chronic Kidney Disease
NCT00308490	PHASE4	COMPLETED	Changes in Iron Markers Following Iron Loading in Hemodialysis Patients
NCT00354692	PHASE4	COMPLETED	Effect of Two Iron Preparations on Protein in the Urine
NCT00593619	PHASE4	SUSPENDED	Trial Comparing the Safety of Two Different Intravenous Iron Formulations
NCT00660933	PHASE4	COMPLETED	Intravenous Iron Versus Oral Iron for Severe Postpartum Anemia
NCT01067547	PHASE4	COMPLETED	A Trial of Iron Replacement in Patients With Iron Deficiency.
NCT01084122	PHASE4	UNKNOWN	Efficacy and Safety of Intravenous Iron Sucrose in Patients With Hip Fracture to Prevent Perioperative Anemia
NCT01151592	PHASE4	WITHDRAWN	Safety Assessment of Iron Sucrose (Venofer) in Patients With Chronic Kidney Disease Who Cannot Tolerate Ferumoxytol (Feraheme) or Iron Dextran (INFed or Dexferrum)
NCT01227616	PHASE4	COMPLETED	Compare Efficacy/Safety of Repeat Doses of Ferumoxytol With Iron Sucrose in CKD Subjects With IDA and on Hemodialysis
NCT02392910	PHASE4	COMPLETED	Hospitalization & Mortality in Patients With Iron Deficiency CKD and HF Treated With i.v. Iron.
NCT02544828	PHASE4	UNKNOWN	Intravenous Iron Sucrose in Arthroplasty
NCT02707757	PHASE4	COMPLETED	Treatment Response in Dialysis Anaemia
NCT05489952	PHASE4	UNKNOWN	Iron Supplementation for Geriatric Hip Fractures
NCT05921968	PHASE4	UNKNOWN	Effect of Lactoferrin Versus Intravenous Iron Sucrose in Treatment of Anemia
NCT06556134	PHASE4	COMPLETED	Oral Liposomal Iron Versus Injectable Iron Sucrose for Anemia Treatment in Non-Dialysis Chronic Kidney Disease Patients
NCT03619850	PHASE3	RECRUITING	A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)
NCT03893045	PHASE3	RECRUITING	A Study to Evaluate Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects
NCT05251493	PHASE3	RECRUITING	Ferric Derisomaltose (Iron Isomaltoside) Versus Iron Sucrose for Treatment of Iron Deficiency in Pregnancy
NCT00202345	PHASE3	COMPLETED	Iron Sucrose in Stage 3/4 Kidney Disease
NCT00236964	PHASE3	COMPLETED	Comparison of Oral Iron With IV Iron in Patients With Anemia of Chronic Renal Failure Not on Dialysis
NCT00384657	PHASE3	WITHDRAWN	Intravenous Iron in Patients With Severe Chronic Heart Failure and Chronic Kidney Disease
NCT00810030	PHASE3	COMPLETED	FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR
NCT01114204	PHASE3	COMPLETED	A Trial Comparing Ferumoxytol With Iron Sucrose for the Treatment of Iron Deficiency Anemia
NCT01222884	PHASE3	COMPLETED	A Randomized, Comparative, Open-label Study of IV Monofer® Administered as Maintenance Therapy by Single or Repeated Bolus Injections in Comparison With IV Iron Sucrose in Subjects With CKD-5D
NCT01857011	PHASE3	COMPLETED	Iron Supplementation for Acute Anemia After Postbariatric Abdominoplasty
NCT02731534	PHASE3	COMPLETED	Efficacy Study of Intravenous Iron Preparation to Iron Deficiency Anemia
NCT02940860	PHASE3	COMPLETED	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease
NCT02940886	PHASE3	COMPLETED	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)
NCT03591406	PHASE3	COMPLETED	To Assess the Impact of Ferric Carboxymaltose Compared With Iron Sucrose in Chinese Subjects on Correcting Iron Deficiency Anaemia
NCT06487299	PHASE2	NOT_YET_RECRUITING	Iron Administration Via Colonic TET Combined With WMT for ID
NCT00960921	PHASE2	WITHDRAWN	Study of the Effects of Iron on Lung Blood Pressure at High Altitude
NCT01052779	PHASE2	COMPLETED	A Trial Comparing Ferumoxytol to Iron Sucrose for the Treatment of Iron Deficiency Anemia in Adult Subjects With Chronic Kidney Disease
NCT01290315	PHASE2	COMPLETED	Intravenous Ferric Carboxymaltose vs IV Iron Sucrose or IV Iron Dextran in Treating Iron Deficiency Anemia in Women
NCT01309659	PHASE2	TERMINATED	Trial To Evaluate the Efficacy of Intravenous Iron in Older Adults With Unexplained Anemia
NCT01438372	PHASE2	WITHDRAWN	IV Iron Sucrose vs Oral FeSO4 in Treating IDA in Pediatric IBD
NCT02047552	PHASE2	WITHDRAWN	RCT of Goal-directed Iron Supplementation of Anemic, Critically Ill Trauma Patients, With and Without Oxandrolone
NCT02977611	PHASE2	WITHDRAWN	The Safety of a High-Dose, Rapid Infusion of Iron Sucrose
NCT03528564	PHASE2	TERMINATED	Hemoglobin Optimization to Prevent Transfusion and Adverse Events in Perioperative Patients With Iron Restricted Anemia
NCT03933813	PHASE1/PHASE2	TERMINATED	Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
NCT00719459	PHASE1	COMPLETED	Bioequivalency Study Comparing Hospira’s Generic Iron Sucrose Injection to Venofer

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).